drugset / Trial / NCT03993379
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
Timeline
- Start
- 2019-11-20
- Primary completion
- 2020-05-21
- Completion
- 2020-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacmilimab | Monoclonal antibody | — | — |
| Background | Ipilimumab | Monoclonal antibody | — | — |